Physician profile
Casey Jean Comte
NPI 1477149698
$5,366.36
in general payments reported to CMS, 2019-2025
19 companies · $3,418 in 2025
The $3,418 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,183 · 2024: $765 · 2025: $3,418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,728 · Travel and Lodging: $1,397 · Education: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,728.04 |
| Travel and Lodging | $1,397.00 |
| Education | $241.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $3,143.14 | 2023-2025 | Inspire |
| Philips North America LLC | $585.30 | 2023-2025 | Vest Therapy Und, (8874) Incourage, Encore |
| Regeneron Healthcare Solutions, INC. | $236.87 | 2024-2025 | Dupixent |
| Glaxosmithkline, LLC. | $219.92 | 2024-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $215.65 | 2024-2025 | Fasenra, Airsupra, Breztri |
| Harmony Biosciences LLC | $197.13 | 2024-2025 | |
| Grifols USA, LLC | $177.74 | 2024-2025 | Prolastin-C Liquid |
| Pulmonx Corporation | $142.83 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.10 | 2024-2025 | Ofev |
| Viatris Specialty LLC | $77.72 | 2025 | Yupelri |
| Jazz Pharmaceuticals INC. | $76.30 | 2025 | |
| Lilly USA, LLC | $38.30 | 2025 | Zepbound |
| Verona Pharma, INC. | $36.90 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $28.46 | 2024 | Yupelri |
| United Therapeutics Corporation | $22.66 | 2025 | Tyvaso |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $21.14 | 2025 | Sunosi |
| Insmed, INC. | $18.67 | 2025 | Arikayce |
| Optinose US, INC. | $17.28 | 2025 | |
| Electromed, INC. | $14.25 | 2023 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Comte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.